Study of BDTX-1535, in Participants With Glioblastoma or Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human, open label, multicenter study to assess the safety, tolerability,
pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of BDTX-1535 in
patients with GBM or NSCLC harboring sensitive EGFR alterations and who have disease
progression following standard of care